Menin Inhibition in Acute Myeloid Leukemia: Rewiring Leukemic Transcriptional Networks
International Journal of Molecular Sciences · 28.05.2026 · 27 (11) · 4886
DOI: 10.3390/ijms27114886 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.05.2026. Verfasst von Ali Tarhini und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Proto-Oncogene Proteins, Gene Regulatory Networks, Gene Expression Regulation, Leukemic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Among the transcriptional dependencies that sustain leukemic identity in acute myeloid leukemia (AML), the menin–KMT2A chromatin complex has emerged as a central regulatory node. The scaffold protein menin, encoded by MEN1, facilitates transcriptional activation of HOX and MEIS family genes during normal hematopoietic development. In AML, this physiologic and developmentally regulated role is co-opted to sustain constitutive HOX/MEIS-driven programs that block differentiation and maintain leukemic potential. Although dependency on menin is most clearly established in KMT2A-rearranged and NPM1-mutated AML, this vulnerability appears to arise from a shared transcriptional state characterized by persistent HOX activation rather than from any single genetic alteration. Pharmacologic disruption of the menin-KMT2A interaction collapses stemness-associated transcriptional networks, promotes myeloid differentiation, and attenuates leukemic self-renewal. Clinical activity observed with menin inhibitors provides translational validation of this dependency and establishes menin inhibition as a differentiation-based therapeutic strategy. In this review, we examine the molecular basis of menin-dependent transcriptional regulation in AML and its implications for therapeutic targeting with menin inhibitors and resistance to therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Ali Tarhini, Aref Al-Kali, Antoine N Saliba
Zitieren
APA
Tarhini, A., Romanos, M., Al-Kali, A., & Saliba, A. N. (2026). Menin Inhibition in Acute Myeloid Leukemia: Rewiring Leukemic Transcriptional Networks. International Journal of Molecular Sciences, 27(11), 4886. https://doi.org/10.3390/ijms27114886
Vancouver
Tarhini A, Romanos M, Al-Kali A, Saliba AN. Menin Inhibition in Acute Myeloid Leukemia: Rewiring Leukemic Transcriptional Networks. International Journal of Molecular Sciences. 2026;27(11):4886. doi:10.3390/ijms27114886
BibTeX
@article{Tarhini2026,
author = {Tarhini, Ali and Romanos, Michael and Al-Kali, Aref and Saliba, Antoine N},
title = {Menin Inhibition in Acute Myeloid Leukemia: Rewiring Leukemic Transcriptional Networks},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {11},
pages = {4886},
doi = {10.3390/ijms27114886}
}
EUVIMED